Objective: The purpose of this study was to conduct a proof-of-concept study to evaluate remote recruitment and assessment of individuals (''virtual research visits'') with Parkinson's disease who have pursued direct-to-consumer genetic testing.
Introduction
Technology is rapidly reshaping genetics and research studies, as new techniques identify the genetic underpinnings of many diseases.
1 Aided by the falling cost of DNA sequencing, 2 consumers can now assess their relative genetic risk for many disorders through direct-toconsumer genetic testing.
3 For example, in Parkinson's disease 16 genetic risk loci have been identified over the past 15 years. 4, 5 Technology and rising drug development costs 6 are fueling novel approaches to conducting clinical research and clinical trials, 7 including enrichment for targeted genotypes, the use of social networks to conduct observational drug studies 8 and virtual clinical trials. 9 New collaborations continue to arise from these trends in genetics and clinical research. For example, the partnership between the direct-to-consumer (DTC) genetics company 23andMe and the Michael J. Fox Foundation for Parkinson's disease research 10,11 has led to genotyping and collection of self-reported outcomes of over 10,000 individuals and currently represents the largest cohort of genotyped individuals with Parkinson's disease. 12 Preliminary analyses of this data have identified new phenotype-genotype associations, risk factors, and differences in disease progression and symptoms associated with factors such as gender and body mass index. 13 This research model has enabled broad and rapid research participation by individuals in 49 states and over 30 countries and allowed for the discovery of new genetic loci associated with Parkinson's disease and replicated previously known associations.
14 The ability to conduct more in-depth assessments and confirm self-reported data in this population could allow larger-scale participation in clinical trials and observational studies which could capture clinician-assessed phenotypic data at a single time point or longitudinally. Therapeutic trials targeted at specific genetic subpopulations could also use remote assessments to facilitate participation among geographically diverse cohorts of genotypically similar individuals. These genetic subpopulations may have different phenotypes, 15 responses to current treatments, 16 and almost certainly will be the preferred study population for future gene-targeted therapies, as has been the case for cancer, 17 and is increasingly the case for other central nervous system disorders. 18 One means of connecting to remote populations is virtual visits. These video visits, conducted via secure video conferencing, are increasingly used for clinical care, 1922 including for Parkinson's disease, 23, 24 but their application to research has been limited to date.
We conducted a proof of concept study aimed at (a) evaluating remote recruitment and assessment of individuals who have undergone DTC genetic testing, (b) assessing the level of agreement of self-reported phenotypic data with that of a specialist, and (c) soliciting feedback on virtual research visits.
Methods

Study design and participants
Members of 23andMe's ''Parkinson's Research Community '' 25 were invited to participate. Eligible members had contributed a DNA sample to 23andMe, reported a diagnosis of Parkinson's disease, completed 23andMe's Parkinson's disease symptom survey developed in collaboration with expert Parkinson's disease clinicians (Appendix 1), and had been active in the 23andMe community in the previous three months. To obtain a convenience sample of 50 participants, a random sample of 166 of these individuals received an email from 23andMe inviting them to participate, and to review and electronically sign the consent document and a data release authorization form. Participants had to have access to a non-public internet-enabled device. Researchers at Johns Hopkins (KCD, ERD) received contact information for interested participants and reviewed consent over the phone. Consenting participants received a web camera (Logitech C110 or C210 model) if needed, and an email link to download secure, Health Insurance Portability and Accountability Act-compliant videoconferencing software from Vidyo (Hackensack, New Jersey, USA), hosted by ID Solutions (Indianapolis, Indiana, USA). The study team (KCD, SD) also provided technical assistance by phone if necessary. Researchers performed a test connection between the remote research site and the participant's home prior to the one-time assessment. The Institutional Review Board at Johns Hopkins Medicine approved the research protocol and consent form.
Assessments
A neurologist (ERD) conducted the 3060 min remote assessment, which was structured to elicit information confirming the participants' responses to the survey participants had completed upon enrollment in the 23andMe project (Appendix 1). Visits, which were modeled similar to a remote clinic visit, 24 included a review of participants' histories, including symptoms of atypical parkinsonian disorders, onset of specific symptoms (age-at-onset of parkinsonian symptoms, falling, urine control problems, light-headedness, and tremor), and family history (first or second degree relative with Parkinson's disease). The specialist completed part IA, non-motor aspects of experiences of daily living, part III, motor examination (excluding rigidity and postural stability tests which require in-person assessment), and part IV, motor complications, of the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS). 26 For the motor portion of the examination, individuals were asked to perform the tasks (e.g. tapping thumb and index finger, walking) in front of the camera, in line with a previous remote study. 23 Visits also included the Montreal Cognitive Assessment, a cognitive assessment tool commonly used in Parkinson's disease. 27, 28 Participants were emailed a copy of the visuospatial/ executive and naming portions, and completed and demonstrated these tasks in the video call before the examiner completed the remainder of the test. The neurologist determined the most likely diagnosis based on the history and examination focused on the cardinal features of parkinsonism that can be assessed remotely (e.g. rest tremor, bradykinesia, and gait difficulties). Parkinson's disease was identified as the diagnosis if it was the most likely explanation for the individual's condition as opposed to other causes of parkinsonism (e.g. multiple system atrophy).
Following completion of the clinical assessments, participants were emailed a survey developed for this study asking about their satisfaction with the virtual research visit, comfort in discussing their condition with the specialist, and willingness to participate in future trials remotely (Appendix 2). Completed surveys were returned via US mail, email, or fax and labeled with participant names. Responses were entered manually into an Excel database.
Analysis
Most of the analyses performed were descriptive. Cohen's kappa coefficient 29 was calculated to determine the level of agreement between the participants' selfreported outcomes on the survey that they initially completed as part of the 23andMe project (Appendix 1) and those assessed by the specialists. The analyses were conducted by NE using Excel.
Results
Study participants and feasibility
A total of 166 individuals were invited to participate, and 103 opened the email invitation. Fifty-four (32%) agreed to participate and 50 (30%) completed the onetime assessment as scheduled between 25 March 20135 June 2013. The reasons for not completing the assessment were: unreachable by phone (n ¼ 2); withdrawal of consent (n ¼ 1); and a scheduling conflict (n ¼ 1). The baseline characteristics of those invited to participate and those that did were generally similar (Table 1 ). The severity of Parkinson's disease among participants varied widely, including duration (mean 9.2 years, range from 228 years), motor signs (mean motor score 31, range from 1852; higher scores indicate greater impairment), and cognitive impairment (mean score on the Montreal Cognitive Assessment was 27, range from 1830; higher scores indicate less impairment). Overall, the characteristics of the participants in this study were similar to those in clinical trials aimed at individuals with moderate Parkinson's disease.
30 Six (12%) participants had genotypes associated with at least 50% increased relative risk of developing Parkinson's disease (Table 1) . The participants came from 23 states and the District of Columbia (Figure 1 ).
Level of agreement
Based on the history and examination, all individuals with self-reported Parkinson's disease were judged by the clinician to have Parkinson's disease (k ¼ 1.00). The level of agreement between the self-reported data and that assessed by the remote clinician was also very high for age of onset (k ¼ 0.97) and presence of family history (k ¼ 0.85) but much lower for the presence of falling (k ¼ 0.59), tremor (k ¼ 0.56), and non-motor symptoms of light-headedness (k ¼ 0.31), and problems with urine control (k ¼ 0.15).
Post-assessment survey
Thirty-eight of the 50 participants (76% response rate) completed the post-assessment survey. Respondents were satisfied or highly satisfied with the virtual research visit and with the specialist's ability to assess their symptoms (95%), and comfortable or very comfortable discussing their condition with the specialist (100%). Nearly all respondents were comfortable or very comfortable (97%) with the software. Satisfaction with connection quality was lower (84% satisfied or very satisfied). Nearly all (95%) reported interest in future virtual research visits, and 87% reported that they would be willing or much more willing to participate in clinical trials if they could do visits remotely from their home.
Discussion
Remote recruitment and conduct of research visits in individuals who have undergone DTC genetic testing is feasible, shows relatively good agreement with selfreported data, and is well received by participants. While the benefits of DTC genetic testing continue to be debated, 1, 2, 11, 3139 this proof of concept study demonstrates its potential to identify, follow, and engage geographically dispersed populations with a given disorder and an underlying genotype in research. 40 Our 32% response rate to a single recruitment email suggests that targeted electronic recruitment in populations unrestricted by geography may improve participation in research studies. Traditional approaches requiring genetic testing of large populations at multiple medical centers require substantial investment in time and resources to satisfy regulatory needs, execute contracts, and conduct in-person assessments at each institution. By contrast, this study took less than three months and utilized a single investigator to assess individuals throughout the country. This approach lays the foundation for larger scale, broader scope studies that can target genetic sub-populations of different disorders and foster partnerships between consumer genetics companies, pharmaceutical firms, academic institutions, and patient communities. We envision the possibility of conducting remote phenotypic assessments in very large cohorts, marrying data from clinical rating scales such as the MDS-UPDRS with genetic information to better characterize and elucidate variability in Parkinson's disease symptoms in relation to genetic markers.
The Institute of Medicine has recently called for such collaborations. In its 2012 workshop on genome-based therapies, the Institute highlighted the need to mobilize patient communities to spur research. 41 In its Rare diseases and orphan products report, one of the key elements of its national strategy to promote rare diseases research and development is ''[timely] 51 This study extends these disruptive models for clinical research by laying the foundation for the inclusion of increasingly available genotypic data into remotely conducted studies.
This study has three key limitations. First, the study population was highly selected only the most recent and active participants in the 10,000-member ''Parkinson's Community'' were asked to participate. These individuals who are highly educated are also more likely to have the internet and technology savvy required to be able to install and operate videoconferencing software, as well as access to high-speed broadband connections, without which remote assessment would be much more difficult. However, many individuals show interest in Parkinson's disease clinical trial participation, including more than 30,000 individuals registered (all remotely) in the Michael J. Fox Foundation's ''Fox Trial Finder'' as of September 2014. 52 Because less than a third (n ¼ 50) of the invited population (n ¼ 166) participated in the study, the results should be interpreted with caution as the low response rate may have resulted in selection bias. Similarly, while the survey response was good (76%), the respondents may have been more satisfied than non-respondents.
Second, some questions used in the background survey on falls, tremor, lightheadedness, and urine control were subjective and non-specific and may have contributed to the low level of agreement with the remote assessment. In addition, while a previous study demonstrated good agreement between remote and inperson assessments of the original UPDRS, 53 remote administrations of the newer MDS-UPDRS and the Montreal Cognitive Assessment scales remain to be validated.
Third, this study only included a one-time assessment. Future studies could be used to evaluate remote research visits in assessing the natural history of different genetic subpopulations, or as a screening or interim assessment in interventional studies.
Notwithstanding these limitations, this study demonstrates the feasibility and potential value of combining phenotypic and genotypic data for research participants across half the country using remote videoconferencing assessments. These novel technology applications and partnerships can accelerate research at low cost and enhance our understanding of the natural history of genetically linked disorders.
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. Gradually . Suddenly . I'm not sure/I don't remember Since you first noticed that you swing your arms less, has this problem. . . .
[free text]
Now we would like to find out more about your average or usual function over the past week, including today. Some patients can do things better at one time of the day than at others. However, only one answer is allowed for each question, so please mark the answer that best describes what you can do most of the time.
Over the past week, have you had trouble going to sleep at night or staying asleep through the night? Consider how rested you felt after waking up in the morning.
. Normal (No problems.) . Slight (Sleep problems are present but usually do not cause trouble getting a full night of sleep.) . Mild (Sleep problems usually cause some difficulties getting a full night of sleep.) . Moderate (Sleep problems cause a lot of difficulties getting a full night of sleep, but I still usually sleep for more than half the night.) . Severe (I usually do not sleep for most of the night.)
Over the past week, have you had trouble staying awake during the daytime?
. Normal (No daytime sleepiness.) . Slight (Daytime sleepiness occurs but I can resist and I stay awake.) . Mild (Sometimes I fall asleep when alone and relaxing. For example, while reading or watching TV.) . Moderate (I sometimes fall asleep when I should not.
For example, while eating or talking with other people.) . Severe (I often fall asleep when I should not. For example, while eating or talking with other people.)
Over the past week, have you had uncomfortable feelings in your body like pain, aches tingling or cramps?
. Normal (No uncomfortable feelings.). . Slight (I have these feelings. However, I can do things and be with other people without difficulty.) . Mild (These feelings cause some problems when I do things or am with other people.) . Moderate (These feelings cause a lot of problems, but they do not stop me from doing things or being with other people.) . Severe (These feelings stop me from doing things or being with other people.)
Over the past week, have you had trouble with urine control? For example, an urgent need to urinate, a need to urinate too often, or urine accidents?
. Normal (No urine control problems. . Normal (Not at all.) . Slight (I am a bit slow but do these activities easily.) . Mild (I have some difficulty doing these activities.) . Moderate (I have major problems doing these activities, but still do most.) . Severe (I am unable to do most or all of these activities.)
Over the past week, have you usually had trouble turning over in bed?
. Normal (Not at all.) . Slight (I have a bit of trouble turning, but I do not need any help.) . Mild (I have a lot of trouble turning and need occasional help from someone else.) . Moderate (To turn over, I often need help from someone else.)
. need to use a walking aid or someone's help.)
The questions in this section will ask about the medications you are taking and have taken in the past.
Which of the following Parkinson's disease medications have you ever taken? Please check all that apply.
. Aricept (donepezil) . Artane (trihexyphenidyl) . Apokyn injection (apomorphine) . Azilect (rasagiline) . Cogentin (benztropine) . Comtan (entacapone) . Eldepryl, Carbex, Atapryl, or Emsam patch (selegiline or deprenyl) . Exelon patch (rivastigimine transdermal system) . Mirapex (pramipexole) . Neupro patch (rotigotine patch) . Parcopa (carbidopa/levodopa orally disintegrating tablet) . Parlodel (bromocriptine) . Permax (pergolide) . Razadyne (galantamine) . Requip (ropinerole) . Sinemet or Atamet (carbidopa/levodopa) . Sinemet CR (controlled release carbidopa/levodopa) . Stalevo (carbidopa, levodopa and entacapone) . Symmetrel (amantadine) . Tasmar (tolcapone) . Some other Parkinson's disease medication . None of the above Which of the following Parkinson's disease medications are you currently taking? Please check all that apply.
. Aricept (donepezil) . Artane (trihexyphenidyl) . Apokyn injection (apomorphine) . Azilect (rasagiline) . Cogentin (benztropine) . Comtan (entacapone) . Eldepryl, Carbex, Atapryl, or Emsam patch (selegiline or deprenyl) . Exelon patch (rivastigimine transdermal system) . Mirapex (pramipexole) . Neupro patch (rotigotine patch) . Parcopa (carbidopa/levodopa orally disintegrating tablet) . Parlodel (bromocriptine) . Permax (pergolide)
. Razadyne (galantamine) . Requip (ropinerole) . Sinemet or Atamet (carbidopa/levodopa) . Sinemet CR (controlled release carbidopa/levodopa) . Stalevo (carbidopa, levodopa and entacapone) . Symmetrel (amantadine) . Tasmar . 1/4 of the day or less . More than 1/4 of the day up to 1/2 the day . More than 1/2 the day up to 3/4 of the day . More than 3/4 of the day up to all day . I'm not sure/I don't remember
The questions in this final section will help us better understand your background and family characteristics.
Has a doctor ever diagnosed any of your biological family members with Parkinson's disease? Please check all that apply. Have you ever had a job where you were regularly exposed to pesticides? Please include herbicides (to kill weeds), fungicides (to kill fungus or mold), insecticides (to kill insects), rodenticides (to kill rodents), or fumigants (a gas used to kill fungus, mold, or insects). Now think about anti-inflammatory medications you have ever taken. These medications are commonly used to treat mild to moderate pain, fever, inflammation or swelling, and sometimes to thin the blood or to protect the heart.
Have you used any of the following types of medications regularly (two or more tablets a week for six months or longer)? Please check all that apply.
. 
